The drugs Ozempic and Wegovy, although developed to treat diabetes, have become wildly popular outside its original target population because it seems to be highly effective in reducing weight as well. This has resulted in it becoming harder for diabetics to gain access to the drugs as well as their price rising.
US senator Bernie Sanders has long been a critic of the pharmaceutical industry and how it charges highly inflated prices in the US that are available for much less elsewhere in the world. He has been successful in pushing for the cost of insulin and asthma inhalers to be drastically reduced and now he is targeting Ozempic and Wegovy.
The blockbuster weight-loss drugs Wegovy and Ozempic are arguably as omnipresent in the American zeitgeist as Taylor Swift or the iPhone. The drugs and others in its class are associated with the sparkle of Hollywood, on the lips of Oprah and considered transformative by doctors.
But the giant market for drugs like Wegovy, including not just the roughly 11% of adults who have diabetes but also the 42% of adults who have obesity, has conjured one of the demons of American healthcare – price.
Americans paid 10 times more for Ozempic than patients in the United Kingdom in 2023 – $936 a month compared with $93. Wegovy costs Americans $1,349 a month, compared with $296 in the Netherlands (the drug is not yet available in the UK).
That wild discrepancy has captured the attention of one of the drug industry’s loudest critics, the US senator Bernie Sanders.
…“What we’re focusing on right now is what may end up being one of the best-selling pharmaceutical products in the history of humanity, and that is Ozempic and Wegovy,” said Sanders. “These are very important gamechangers helping people with diabetes and obesity.”
Sanders is preparing to square up against the chief executive of the Danish pharmaceutical giant that makes both drugs, Novo Nordisk. Under threat of subpoena, its CEO, Lars Fruergaard Jørgensen, agreed to testify before the same committee in September. But even for Sanders, the challenge is formidable.
“You’re taking on a company which will make billions of dollars every single year, many billions of dollars from the US, on just this product,” said Sanders. “So, do I think this is going to be a difficult challenge? I do.”